Health economics
2026-04-26
9 minute read
12 sources
GLP-1 at the Medicare Bargaining Table: Ozempic, Wegovy, and the 2027 Pricing Reset
Medicare's first negotiated prices took effect January 2026 across ten high-spend drugs. Cohort two, effective 2027, now includes Ozempic. The implications for Novo Nordisk, Eli Lilly, compounding telehealth, and global access stretch from Indianapolis to Indore.
The Inflation Reduction Act's drug price negotiation program moves from theory to invoice. CMS published Maximum Fair Prices for the first ten Part D drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog) effective January 1, 2026, with discounts ranging from 38 to 79 percent off 2023 list (CM...